that both types are associated with faster rates of decline in cognition [17, 18] . Additionally, several studies point to type 2 DM playing a role in the acceleration of AD progression [19] .
Introduction
Late-onset Alzheimer's disease (AD) is a progressive neurodegenerative disease and the leading cause of dementia in the United States, afflicting up to 20% of individuals 75-84 years of age and nearly 50% of individuals over 85 [1] . The implications are serious considering that the fastest growing population in the United States consists of adults over the age of 65 [2, 3] . AD is characterized neuropathologically by aggregates of intraneuronal hyperphosphorylated tau protein and extracellular amyloid beta protein (Aβ) [4, 5] .
These changes evolve over decades and progress in predictable spatial and temporal patterns-the hippocampus being one of the earliest regions affected [6] . While much attention has been paid to the progression of these diagnostic markers, less attention has been focused on what role cortical microvasculature alterations many play in the development and progression of AD neuropathology. Despite the fact that there is often a coexistence of neurodegenerative and vascular pathology in the aging brain [7] , there are few quantitative observations of how the cortical vasculature is affected [8] . Hypertension (HTN) and diabetes mellitus (DM), two common cardiovascular risk factors, both damage cortical microvasculature and both increase risk for developing AD. HTN, currently defined as a systolic blood pressure above 140 mm Hg and/or a diastolic blood pressure above 90 mm Hg [9] , is estimated to affect 25% of the general population [10] and over one half of persons over 65 years [11] . HTN is the most significant risk factor for cerebrovascular disease [12] . Several longitudinal studies have suggested that hypertension, particularly during or after midlife, is associated with an increase risk for AD, and several randomized placebocontrolled clinical trials have found that the treatment of HTN with antihypertensive drugs has decreased AD risk [13] . DM is estimated to affect more than 10% of the elderly population in the United States [14] . Type 1 DM is characterized by the progressive inability of pancreatic beta cells to produce insulin, and type 2 DM is characterized by progressive impaired response to insulin [15] . Increased glucose levels in the blood are common to both types, and it is elevation in glucose levels that is thought to damage blood vessels. It is estimated that up to 80% of deaths in diabetic patients are associated with vascular disease [16] . Several longitudinal studies have shown have quantified this information. In this study, we used stereologic approaches to quantify the hippocampal microvasculature in the CA1 and CA3 fields, two areas that are differently affected in AD progression (Figure 1 ), in AD and non-AD cases. Furthermore, we subdivided these two groups (AD vs non-AD) into further categories according to cardiovascular risk factor (no risk, type 2 DM, or hypertension) to assess whether the presence of a cardiovascular risk factor preferentially affects hippocampal microvasculature length density. Rating score is based on subject interview (or informant interview, in cases of more severe dementia) and characterizes loss in cognitive and functional performance in six domains; memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care (CDR score 0 = no dementia, 1 = mild, 2 = moderate, 3 = severe, 4 = profound, 5 = terminal dementia) [20, 21] . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) scores are based on semiquantitative findings -an observational rating of the frequency of neuritic plaques (NPs) and neurofibrillary tangles (NFTs), which is then related to age to give a score (0 = none, 1 = sparse, 3 = moderate, 5 = severe) [22] . It should be noted that the CERAD protocol does not take in to account estimates of soluble amyloid load, aberrant tau accumulation, and synaptic density, nor does it assess vascular pathology [23, 24] . In addition, the CERAD sampling does not employ a systematic-random approach and is based on assumption of homogeneous distribution of lesions in the tissue, in part explaining why some of the cases used in this study in the non-AD groups exhibited higher CERAD scores than anticipated. The right hemispheres of the brain from these patients were fixed in 4% paraformaldehyde, and matching hippocampal blocks were prepared immediately prior to the time of this study.
experimental procedures

Tissue processing and Immunohistochemistry
We carried out this study in the hippocampus as it is an area affected early in AD, and where 
Stereology
All analyses were performed blind to medical history and subject group to reduce bias.
Sections were first viewed at low magnification 
Statistics
All analyses were performed separately for the CA1 and CA3 fields. The distribution of length density was examined for non-normality.
A two-way analysis of variance (ANOVA) was performed, testing length density differences by group (AD vs non-AD) and cardiovascular risk factor (no risk factor, HTN, DM). If the interaction was not significant, the primary analysis for group differences regardless of presence or absence of diagnosis of a cardiovascular risk factor was assessed using one way ANOVA. Group differences in the standard deviation (SD) were assessed using 
results
CA1
The distribution was not markedly nonnormal (skewness = 1.147; kurtosis = 0.845).
The most extreme observation was only 2. 
CA3
The distribution was not markedly non-normal 
discussion
Cerebral microvascular pathology is known both to precede and progress along age-related cognitive decline [30, 31] . Cerebrovascular pathology is also present in AD. Classic AD microvasculature alterations that have been qualitatively described include a thinning of microvessels (termed "string vessels") [32] , increased tortuosity [33] and vessel fragmentation [34] , with alterations most often localized in regions that contain a high amount of AD-related pathology [35] . Vascular changes such as a decrease in density, an increased presence of loop formations, and atrophic vessels can also be seen in other types of dementias [7] . Our own observations of the samples used in this study fit the known descriptions of vasculature change seen in AD cases (Figure 3 ), however they differ in that we observed in AD prior to AD onset. The CA1 field is sensitive to metabolic stress caused by ischemic injury and hypoxia [38] . Hypoperfusion for 30 minutes has been shown to lead to a typical neuronal response termed "delayed neuronal death" that occurs selectively in CA1 field neurons [39, 40] .
This apoptotic response, induced by glutamate and calcium, occurs 1-3 days following ischemia and hypoxia [41, 42] . Taking [43] , and this reduction in blood flow can be observed in the early stages of AD in areas where there is an association between the reduction in blood flow and tau accumulation [44, 45] . Another possibility is that oxidative stress caused by reduction in cerebral blood flow (which occurs in both aging and AD) [46] renders the microenvironment more susceptible to AD pathological change, and oxidative stress has been shown to cause aggregation of both Aβ [47] and tau [48] . It has also been proposed that angiogenic vascular endothelial growth factor becomes sequestered in AD by binding to Aβ, decreasing its ability to promote vessel growth [49] . In such a scenario one can see how if vascular damage increases the risk for AD, and AD worsens vascular damage, a cycle could be initiated that ultimately would accelerate both pathologies.
We did not observe a comparable increase in mean length density or its variance in the CA3 fields in either the AD or non-AD group. There is also associated with an increased rate of cognitive decline [18] and HTN is associated with decreased cognitive function [52] . There are several theories concerning how HTN affects AD and cognitive decline. The first is that HTN causes vascular change that predisposes to an increased rate of lacunar and cortical infarcts [53] , and a second is that HTN accelerates the production of Aβ [54] . There are also multiple theories in regards to the mechanism that link DM and dementia -DM predisposes to ischemia induced cerebrovascular disease [55] , hyperglycemia can cause neuronal toxicity through oxidative stress and accumulation of glycation end-products [56, 57] , and insulin can directly affect the metabolism of Aβ [58] . for cognitive impairment [59] . Multiple studies have in fact shown that the presence of cerebrovascular lesions may participate in determining dementia severity by causing a worsening of clinical symptoms at lower levels of AD pathology [60] [61] [62] [63] , which could account for the breakdown of the correlation in groups with both AD and a risk factor. It is here also important to note that vascular dementia and AD dementia are often hard to distinguish, and it is also possible that, when they do coexist, cerebrovascular pathology may prevent an accurate diagnosis of AD [59] . Thus it is possible that cases in our study who were placed into the non-AD, risk factor groups may in fact belong in the AD, risk factor groups. It is also important to address the sample size used in this study, which was dictated by the availability of cases that met our criteria. We recognize that this is a limitation, and that our results are in this respect preliminary yet indicative of a pathological process that interacts with the usual course of AD.
Finally, although our sample size for each group is small, it is striking that 3 out of the 4 cases with both AD and DM had the most severe CDR score rating of 5. Thus in the group with both AD and DM, it appears that there is a worsening of dementia in the context of microvasculature length density changes similar to cases with AD alone and cases with AD and HTN. A study utilizing autopsy specimens found that type 2 DM is in fact negatively associated with AD neuropathologic changes, and put forth the hypothesis that the cognitive impairments associated with DM likely reflect the impact of metabolic and microvascular change and the interaction that such changes have with NPs and NFTs [64] . This is consistent with the findings of an earlier postmortem study that show that DM is not a risk factor of AD-type pathology, and also suggests that there are other factors at play in AD that worsen cognitive decline [65] . The findings of yet another study show that in non-diabetic subjects, dementia is associated with increased Aβ accumulation, while in cases with diabetes, dementia is associated more with neuroinflammation and microvascular infarct [66] . It is possible that the mechanisms introduced by DM pathology affect microvasculature in way not identifiable by quantification (such as vessel integrity). The cognitive decline associated with diabetes has been found to progress slowly over a long time period [68] and it has been observed that HTN in the form of increased systolic blood pressure in midlife increases the risk for developing AD later in life [69, 70] . It is also possible that clinical symptoms of AD occur late in disease progression, and that AD-associated neurodegeneration actually begins in midlife [71] [72] [73] . It remains to be seen how cortical microvasculature alterations may play a role during the early stages of AD development. The study's sponsors did not play a role in study design, data analysis or interpretation, or paper preparation and submission.
